Participant-Reported Outcomes With Long-Acting Lenacapavir-Based Regimens Among Heavily Treatment-Experienced People Living With HIV in the CAPELLA Clinical Trial



Moti Ramgopal<sup>1</sup>, Dylan J Mezzio<sup>2</sup>, Keith Dunn<sup>2</sup>, Shan-Yu Liu<sup>2</sup>, Xiu Chen<sup>2</sup>, Antonella Castagna<sup>3</sup>, Martin S Rhee<sup>2</sup>

<sup>1</sup>Florida State University, Fort Pierce, FL, USA; <sup>2</sup>Gilead Sciences, Inc., Foster City, CA, USA; <sup>3</sup>Università Vita-Salute San Raffaele, Milan, Italy

# **Key Findings**

- In the CAPELLA trial, fewer participants reported symptoms as bothersome at week 52 vs baseline, with decreases in HIV-SI scores ranging from 1% to 15%
- EQ-5D-5L index and VAS scores, SF-36 physical and mental component summary scores, and NPRS scores were stable through 52 weeks

## Conclusions

- In the CAPELLA trial, these PRO results demonstrate high, stable HRQoL over time, supporting the tolerability of SC lenacapavir plus OBR
- The PRO results for HTE PLWH align with the favorable safety profile and low discontinuation rates of lenacapavir



Previously reported high rates of virologic suppression and increases in CD4+ cell count with lenacapavir treatment may help explain how this population of HTE PLWH had decreased symptom severity while staying within adult US norms for EQ-5D-5L and SF-36 measures



These data, reflecting the perspectives of the people treated, highlight the potential for lenacapavir plus OBR to decrease most HIV symptoms, without compromising HRQoL, for HTE PLWH

# Introduction

- Heavily treatment-experienced (HTE) people living with HIV (PLWH) and multidrug resistance have limited treatment options and often have low CD4+ T-cell counts<sup>1-4</sup>
- The baseline mean EQ-5D-5L index and visual analogue scale (VAS) scores for all participants were 0.870 and 81.0, respectively (compared \_\_\_\_ with US adult population norms of 0.851 and 80.47, respectively)
- For all participants at week 52, the mean change from baseline values for the index and VAS scores were -0.06 and 3, while the minimal important change (MIC) values are 0.063 and 7.0
- Both mean EQ-5D-5L scores remained stable over time; mean scores stayed within the MIC thresholds for improving or worsening
- Low CD4+ T-cell counts have significant negative impacts on health—increasing the risk of opportunistic infections, comorbidities, and death—and on health-related quality of life (HRQoL)<sup>2,3</sup>
- Lenacapavir is a first-in-class capsid inhibitor that can be administered subcutaneously (SC) twice a year<sup>5,6</sup>
- · Lenacapavir is approved in various regions for HTE PLWH with multidrug resistance when used in combination with an optimized background regimen (OBR)7-11
- In the ongoing Phase 2/3 CAPELLA study (NCT04150068), SC lenacapavir added to an OBR led to high rates of virologic suppression and was generally well tolerated by HTE PLWH<sup>12</sup>
- At week 52, a viral load of <50 copies/mL was reported in 78% of participants, with a mean increase in the CD4+ cell count of 97 cells/mm<sup>3</sup>
- No serious adverse events related to lenacapavir were reported and only 1 participant discontinued at week 52 due to an injection site reaction (nodule; Grade 1)


# **Objective**

To assess participant-reported outcomes (PROs) related to HIV symptoms, injection pain, and overall HRQoL in the CAPELLA study among HTE PLWH treated with lenacapavir in combination with an OBR

# **Methods**

The study design for CAPELLA was described previously<sup>6</sup>

### Figure 1. CAPELLA study design



\*Oral LEN administered as 600 mg on days 1 and 2 and 300 mg on day 8; SC LEN administered as 927 mg (2 × 1.5 mL) in the abdomen on day 15.

ARV, antiretroviral; ATV, atazanavir; d, day; LEN, lenacapavir; OBR, optimized background regimen (investigational agents, such as fostemsavir, were allowed; ATV, ATV/cobicistat, ATV/ritonavir, efavirenz, entecavir, nevirapine, and tipranavir were not allowed); Q6M, every 6 months; SC, subcutaneous

Scores from 4 validated PRO instruments were collected at baseline and through week 52

## Figure 3. Mean SF-36 physical component summary scores (A) and mental component summary scores (B) by visit

100

80


60

20

BL 4




Α



BL refers to day 1 of the trial. Higher SF-36 scores indicate better functioning than lower scores BL. baseline: SF-36. Short Form 36

- At baseline, the mean Short Form-36 (SF-36) physical component and mental component summary scores for all participants were 48.5 and 48.4, respectively, compared with US norms of 50 for each component score<sup>14</sup>
- Among all participants, the mean change from baseline values in SF-36 physical component and mental component summary scores were 1.0 and -0.9 at week 52, while the MIC values are 2.0 and 3.0, respectively
- Both SF-36 component summary scores were stable through 52 weeks; mean scores stayed within the MIC thresholds for improving or worsening

#### Figure 4. Proportion of individuals who reported each symptom as at least a little bothersome (HIV-SI ≥2) among all participants



#### Table 1. Participant-reported outcome instruments

PRO instrument	Description	Scale range	
EQ-5D-5L (index score and VAS) <sup>13</sup>	Provides insights into HRQoL and how health conditions may limit or worsen daily activities	Index score = $0-1$ ; VAS = $0-100$ , where higher values indicate better health	
SF-36 <sup>14</sup>	Examines 8 dimensions of physical and mental health and function	0–100 with norm-based scoring (mean = 50, SD = 10), where higher scores indicate better health	
HIV-SI <sup>15</sup>	Assesses 20 common symptoms associated with HIV treatment or disease	0-4 with higher scores indicating more bothersome symptoms; scores were dichotomized as not bothersome ( $0-1$ ) and bothersome ( $2-4$ )	
NPRS <sup>16</sup>	Assesses pain intensity at the time of the most recently received injection	0–10, where higher scores indicate worse pain	

HIV-SI, HIV-Symptom Index; HRQoL, health-related quality of life; NPRS, numeric pain rating scale; PRO, participant-reported outcome; SF-36, Short Form-36; VAS, visual analogue scale.

## Results


#### Table 2. Baseline characteristics

	Cohort 1		Cohort 2	
Characteristic	LEN (n = 24)	Placebo (n = 12)	LEN (n = 36)	All participants (N = 72)
Age, median (range), years	55 (24–71)	54 (27–59)	49 (23–78)	52 (23–78)
Sex, female	7 (29)	3 (25)	8 (22)	18 (25)
Race				
Black	10 (42)	6 (55)	11 (31)	27 (38)
White	12 (50)	4 (36)	13 (36)	29 (41)
Asian	2 (8)	1 (9)	12 (33)	15 (21)
Data could not be collected	0	1 (9)	0	1 (1)
<b>Viral load</b> , median (range), log <sub>10</sub> copies/mL	4.2 (2.3–5.4)	4.9 (4.3–5.3)	4.5 (1.3–5.7)	4.5 (1.3–5.7)
<b>CD4+ count</b> , median (range), cells/mm <sup>3</sup>	172 (16–827)	85 (6–237)	195 (3–1296)	150 (3–1296)
<200 cells/mm <sup>3</sup>	16 (67)	11 (92)	19 (53)	46 (64)
Resistance to ≥2 drugs in major class				
NRTI	23 (96)	12 (100)	36 (100)	71 (99)
NNRTI	22 (92)	12 (100)	36 (100)	70 (97)
Protease inhibitor	20 (83)	8 (67)	30 (83)	58 (81)
INSTI	20 (83)	7 (58)	23 (64)	50 (69)
All 4 major classes	14 (58)	3 (25)	16 (44)	33 (46)
Median overall susceptibility score of OBR <sup>a</sup>	2.0	1.3	2.0	2.0
Number of fully active agents in the OBR				
0	4 (17)	2 (17)	6 (17)	12 (17)
1	7 (29)	7 (58)	13 (36)	27 (38)
≥2	13 (54)	3 (25)	17 (47)	33 (46)

Data are n (%) unless otherwise specified.

<sup>a</sup>The drug susceptibility score to an individual antiretroviral medication was deemed according to a proprietary algorithm, with 1.0=full susceptibility, 0.5=partial susceptibility, and 0=no susceptibility. The overall susceptibility score of the optimized background therapy was the sum of the individual scores. For historical resistance reports, the scores were derived from data provided by the investigators CD, cluster of differentiation; INSTI, integrase strand transfer inhibitor; LEN, lenacapavir; NNRTI, non-nucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; OBR, optimized

#### Figure 5. Mean NPRS scores by visit



symptoms reported as bothersome were fatigue or loss of energy (-15%), nervous or anxious (-14%), and muscle aches or

Cohort 1 📥 Cohort 2 🔶 Total 🗕 – – US norm

26

36

34

70

Week

16

35

33

68

52

35

29

64

A few symptoms increased  $\geq$ 5% by week 52, including headache and pain, numbness, or tingling in the hands or feet

Baseline refers to day 1 of the trial. Percentages in the plot are based on participants responding 2 ("it bothers me a little"), 3 ("it bothers me"), and 4 ("it bothers me a lot") on the HIV-SI response scale. \* $\geq$ 5% decrease at week 52 vs baseline. † $\geq$ 5% increase at week 52

- Mean Numeric Pain Rating Scale (NPRS) score ranged from 3.9 to 5.1 through week 52 for all participants
- At week 52 among all participants, the mean change from baseline was less than the MIC of 2.0, and so did not represent a meaningful change
- While individual NPRS scores were highly variable over time with no clear trend, the mean score remained stable
- BL refers to the day of the first SC injection. Higher NPRS
- scores indicate worse pain BL, baseline; N/A, not applicable; NPRS, Numeric Pain
- Rating Scale; SC, subcutaneous.

## Limitations


The number of study participants was small (N = 72)

The general inherent limitations of participant-reported outcome instruments apply \_\_\_\_

background regimen.

- A total of 72 participants were enrolled, with each cohort consisting of 36 participants \_\_\_\_
- The median age (range) for all participants was 52 (23–78) years
- Among all participants, 64% had <200 CD4+ cells/mm<sup>3</sup>
- Overall, 22% of participants had a baseline CD4+ count of <50 cells/mm<sup>3</sup>

#### Figure 2. Mean EQ-5D-5L index scores (A) and VAS scores (B) by visit



BL refers to day 1 of the trial. Higher EQ-5D-5L scores indicate better quality of life. EQ-5D-5L index scores range from 0-1. BL, baseline; VAS, visual analogue scale.

- Interpretation of scales may differ from participant to participant (ie, an HRQoL score signifying poor health to some may be considered as the best possible health for others)
- The EQ-5D-5L and SF-36 instruments—general measures of health—may not be specific or sensitive enough to detect differences between subgroups in this participant population
- Due to the heterogeneous nature of the OBR, which often contains antiretrovirals with varied safety profiles, it is difficult to infer causal association with LEN

References: 1. Priest J, et al. Open Forum Infect Dis. 2021;8(12):ofab562. 2. Anis AH, et al. J Acquir Immune Defic Syndr. 2009;51(5):631-9.

3. Joyce VR, et al. J Acquir Immune Defic Syndr. 2009;50(1):27-36. 4. Ledergerber B, et al. Lancet. 2004;364(9428):51-62. 5. Dvory-Sobol H, et al. Curr Opin HIV AIDS. 2022;17(1):15-21. 6. Segal-Maurer S, et al. N Engl J Med. 2022;386(19):1793-803. 7. Sunlenca (lenacapavir). European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/ sunlenca. Accessed May 26, 2023. 8. Sunlenca (lenacapavir). Government of Canada Website. https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102149. Revised May 25, 2023. Accessed May 26, 2023. 9. Gilead Sciences, Inc. Dec 22, 2022. Sunlenca® (lenacapavir) receives FDA approval as a first-in-class, twice-yearly treatment option for people living with multi-drug resistant HIV [Press release]. https://www.gilead.com/news-and-press/press-room/press-releases/2022/12/sunlenca-lenacapavir-receives-fda-approvalas-a-firstinclass-twiceyearly-treatment-option-for-people-living-with-multidrug-resistant-hiv. 10. Gilead Sciences, Inc. Aug 22, 2022. Gilead announces first global regulatory approval of Sunlenca® (lenacapavir), the only twice-yearly HIV treatment option [Press release]. https://www.gilead.com/news-and-press/press-room/press-releases/2022/8/gilead-announces-first-<u>global-regulatory-approval-of-sunlenca-lenacapavir-the-only-twiceyearly-hiv-treatment-option</u>. **11.** US FDA. Dec 22, 2022. FDA approves new HIV drug for adults with limited treatment options [Press release]. https://www.fda.gov/news-events/press-announcements/fda-approves-new-hiv-drug-adults-limited-treatment-options. 12. Ogbuagu O, et al. Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People With Multi-Drug Resistant HIV: Week 52 Results. Oral presentation presented at: IDWeek; 2022; Washington, D.C. 13. Herdman M, et al. Qual Life Res. 2010(10):1727-36. 14. Ware JE, et al. QualityMetric. 2007. 15. Justice AC, et al. J Clin Epidemiol. 2001;54 Suppl 1:S77-90. **16.** Farrar JT, et al. *Pain*. 2001;94(2):149-58. **17.** Jiang R, et al. *Qual Life Res*. 2021;30(3):803-16.

Acknowledgments: We express our sincere gratitude to all participants who gave informed consent to participate in the CAPELLA trial and to the study investigators. We wish to also thank Hadas Dvory-Sobol, PhD, for consultation and involvement in the trials and Shaolan (Shirley) Xiang, MS, and Hui Wang, PhD, for supporting data review. Finally, we thank George Skingley, BSc; Mike Greenwood, BSc; and Kim Cocks, PhD, from Adelphi Values UK for advice on data presentation and interpretation. This study was funded by Gilead Sciences, Inc. Medical writing support was provided by Atreju Lackey, PhD, of AlphaScientia, a Red Nucleus company, and was funded by Gilead Sciences, Inc.

Disclosures: MR reports no conflicts of interest. AC reports funding, advisory board, speaker panel, and preparation of educational materials from ViiV Healthcare; Gilead Sciences, Inc.; Merck Sharp and Dohme; Janssen; and Cilag. DJM, KD, S-YL, XC, and MSR are employees of Gilead Sciences, Inc., and may hold stock optoins.

International AIDS Society (IAS) 2023, the 12th IAS Conference on HIV Science, July 23–26, Brisbane, Australia